You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 441 Outcomes of patients with metastatic renal cell carcinoma with intermediate- or poor-risk symptomatic disease who received their first cycle of nivolumab and ipilimumab while being hospitalized

Alerts

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Combination immunotherapies
441 Outcomes of patients with metastatic renal cell carcinoma with intermediate- or poor-risk symptomatic disease who received their first cycle of nivolumab and ipilimumab while being hospitalized
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address